☰

Oriana E. Hawkins, Ph.D. - Publications

Affiliations: 
2010 University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States 
Area:
Immunology
Tree Info Similar researchers PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Sai J, Owens P, Novitiskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik-Delmaire T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, et al. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Anti-tumor Immunity and Anti-PD1 Responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28003307 DOI: 10.1158/1078-0432.Ccr-16-2142  0.331
2015 Patterson AM, Kaabinejadian S, McMurtrey CP, Bardet W, Jackson KW, Zuna RE, Husain S, Adams GP, MacDonald GC, Dillon RL, Ames H, Buchli R, Hawkins OE, Weidanz JA, Hildebrand WH. Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer. Molecular Cancer Therapeutics. PMID 26719579 DOI: 10.1158/1535-7163.Mct-15-0658  0.753
2015 Weidanz JA, Doll KL, Mohana-Sundaram S, Wichner T, Lowe DB, Gimlin S, Wawro Weidanz D, Magnusson R, Hawkins OE. Detection of human leukocyte antigen biomarkers in breast cancer utilizing label-free biosensor technology. Journal of Visualized Experiments : Jove. PMID 25867039 DOI: 10.3791/52159  0.569
2015 Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, et al. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Research. 75: 181-93. PMID 25398437 DOI: 10.1158/0008-5472.Can-14-2405  0.334
2015 Kaabinejadian S, Patterson A, Bardet W, Jackson K, McMurtrey C, Wichner T, Hawkins O, Weidanz J, Hildebrand W. OR27 Monoclonal antibody RL41A recognizes cisplatin resistant ovarian cancer cells via HLA-A2 Human Immunology. 76: 11. DOI: 10.1016/J.Humimm.2015.07.019  0.656
2014 Yang J, Hawkins OE, Barham W, Gilchuk P, Boothby M, Ayers GD, Joyce S, Karin M, Yull FE, Richmond A. Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response. Cancer Research. 74: 7274-84. PMID 25336190 DOI: 10.1158/0008-5472.Can-14-1091  0.34
2014 Kim S, Pinto AK, Myers NB, Hawkins O, Doll K, Kaabinejadian S, Netland J, Bevan MJ, Weidanz JA, Hildebrand WH, Diamond MS, Hansen TH. A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice. European Journal of Immunology. 44: 1936-46. PMID 24723377 DOI: 10.1002/Eji.201444450  0.633
2013 Crowder SW, Horton LW, Lee SH, McClain CM, Hawkins OE, Palmer AM, Bae H, Richmond A, Sung HJ. Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 2788-98. PMID 23568779 DOI: 10.1096/Fj.13-228288  0.356
2012 Hawkins OE, Richmond A. The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Research : Bcr. 14: 103. PMID 22293321 DOI: 10.1186/Bcr3092  0.452
2011 Weidanz JA, Hawkins O, Verma B, Hildebrand WH. TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells. International Reviews of Immunology. 30: 328-40. PMID 22053972 DOI: 10.3109/08830185.2011.604880  0.723
2011 Greene JM, Wiseman RW, Lank SM, Bimber BN, Karl JA, Burwitz BJ, Lhost JJ, Hawkins OE, Kunstman KJ, Broman KW, Wolinsky SM, Hildebrand WH, O'Connor DH. Differential MHC class I expression in distinct leukocyte subsets. Bmc Immunology. 12: 39. PMID 21762519 DOI: 10.1186/1471-2172-12-39  0.626
2011 Hawkins O, Verma B, Lightfoot S, Jain R, Rawat A, McNair S, Caseltine S, Mojsilovic A, Gupta P, Neethling F, Almanza O, Dooley W, Hildebrand W, Weidanz J. An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer. Journal of Immunology (Baltimore, Md. : 1950). 186: 6607-16. PMID 21515791 DOI: 10.4049/Jimmunol.1003995  0.758
2011 Southwood S, Solomon C, Hoof I, Rudersdorf R, Sidney J, Peters B, Wahl A, Hawkins O, Hildebrand W, Mothé BR, Sette A. Functional analysis of frequently expressed Chinese rhesus macaque MHC class I molecules Mamu-A1*02601 and Mamu-B*08301 reveals HLA-A2 and HLA-A3 supertypic specificities. Immunogenetics. 63: 275-90. PMID 21274527 DOI: 10.1007/S00251-010-0502-8  0.619
2010 Verma B, Hawkins OE, Neethling FA, Caseltine SL, Largo SR, Hildebrand WH, Weidanz JA. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties. Cancer Immunology, Immunotherapy : Cii. 59: 563-73. PMID 19779714 DOI: 10.1007/S00262-009-0774-8  0.753
2009 Loffredo JT, Sidney J, Bean AT, Beal DR, Bardet W, Wahl A, Hawkins OE, Piaskowski S, Wilson NA, Hildebrand WH, Watkins DI, Sette A. Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. Journal of Immunology (Baltimore, Md. : 1950). 182: 7763-75. PMID 19494300 DOI: 10.4049/Jimmunol.0900111  0.645
2009 Hawkins O, Neethling F, Lightfoot S, May R, Blakey G, Dooley W, Weidanz J, Hildebrand W. 276-P: Monoclonal antibody specific for an ornithine decarboxylase peptide/HLA A*0201 complex confirms presentation of the peptide on primary breast tumor Human Immunology. 70: S150. DOI: 10.1016/J.Humimm.2009.09.309  0.708
2009 Tian R, Cox D, Mojsicovic D, Hawkins O, Watkins D, Hildebrand W. 2-OR: Cynomolgus macaque MHC class I molecules present HLA-A and HLA-B like peptides Human Immunology. 70: S1. DOI: 10.1016/J.Humimm.2009.09.011  0.684
2008 Hawkins OE, Vangundy RS, Eckerd AM, Bardet W, Buchli R, Weidanz JA, Hildebrand WH. Identification of breast cancer peptide epitopes presented by HLA-A*0201. Journal of Proteome Research. 7: 1445-57. PMID 18345606 DOI: 10.1021/Pr700761W  0.795
2008 Hawkins O, VanGundy R, Eckerd A, Bardet W, Buchli R, Weidanz J, Hildebrand W. 107 POSTER Novel epitopes presented by the HLA-A*0201 are recognized by the cytotoxic T lymphocytes of breast cancer survivors European Journal of Cancer Supplements. 6: 36. DOI: 10.1016/S1359-6349(08)72039-1  0.471
2008 Hawkins O, VanGundy R, Eckerd A, Bardet W, Buchli R, Weidanz J, Hildebrand W. 34-OR: Cytotoxic T lymphocytes of breast cancer survivors recognize novel epitopes presented by the HLA-A*0201 Human Immunology. 69: S115. DOI: 10.1016/J.Humimm.2008.08.241  0.674
2007 Tian R, Wahl AR, Hawkins O, O’Connor D, Hildebrand WH. 15-OR: Endogenously loaded Cynomolgus – macaque MHC class I peptides Human Immunology. 68. DOI: 10.1016/J.Humimm.2007.08.021  0.677
2007 Hawkins OE, VanGundy RS, Bardet W, Fleshman A, Buchli R, Hildebrand WH. 12-OR: Analysis of breast cancer peptide epitopes presented by HLA-a*0201 Human Immunology. 68. DOI: 10.1016/J.Humimm.2007.08.018  0.763
2006 Tian R, Wahl AR, Hawkins O, Bardet W, O’Connor D, Hildebrand WH. 48-OR: Characterization of endogenously loaded Cynomolgus macaque MHC class I peptides Human Immunology. 67. DOI: 10.1016/J.Humimm.2006.08.058  0.678
2005 Hawkins O, Gonzalez M, Gilb A, Potapova T, Hildebrand W. MHC class I peptide analysis from a breast cancer cell line transfected with sHLA Human Immunology. 66: 117. DOI: 10.1016/J.Humimm.2005.08.223  0.59
Show low-probability matches.